Vaishali Sanchorawala, MBBS

Professor, Medicine

Vaishali Sanchorawala
732 Harrison Ave

Biography

Expertise includes: AL amyloidosis – clinical trials, treatment; Stem cell transplantation; Myeloma.

Other Positions

  • Director, Amyloidosis Center, Boston University School of Medicine
  • Active Staff Hospital Privileges, Medicine, Boston Medical Center

Education

  • Seth G.S. Medical College, MBBS

Classes Taught

Publications

  • Published on 1/5/2018

    Hari P, Lin HM, Asche CV, Ren J, Yong C, Luptakova K, Faller DV, Sanchorawala V. Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. Amyloid. 2018 Jan 05; 1-7. PMID: 29303358.

    Read at: PubMed
  • Published on 12/21/2017

    Nguyen VP, Brauneis D, Kaku M, Sloan JM, Sarosiek S, Quillen K, Shelton AC, Sanchorawala V. Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant. 2017 Dec 21. PMID: 29269794.

    Read at: PubMed
  • Published on 12/7/2017

    White MK, McCausland KL, Sanchorawala V, Guthrie SD, Bayliss MS. Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples. Patient Relat Outcome Meas. 2017; 8:157-167. PMID: 29263707.

    Read at: PubMed
  • Published on 12/6/2017

    Ding Y, Francis J, Gautam A, Pelletier L, Sanchorawala V, Quillen K. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection?. Clin Nephrol. 2017 Dec 06. PMID: 29208204.

    Read at: PubMed
  • Published on 9/1/2017

    Batalini F, Econimo L, Quillen K, Sloan JM, Sarosiek S, Brauneis D, Havasi A, Stern L, Dember LM, Sanchorawala V. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Biol Blood Marrow Transplant. 2018 Jan; 24(1):127-132. PMID: 28865972.

    Read at: PubMed
  • Published on 9/1/2017

    Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017 Sep 01; 18(9):1057-1064. PMID: 27965280.

    Read at: PubMed
  • Published on 8/29/2017

    Sanchorawala V, McCausland KL, White MK, Bayliss MS, Guthrie SD, Lo S, Skinner M. A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time. Br J Haematol. 2017 Nov; 179(3):461-470. PMID: 28850697.

    Read at: PubMed
  • Published on 7/24/2017

    Arun M, Brauneis D, Doros G, Shelton AC, Sloan JM, Quillen K, Ruberg FL, Sanchorawala V, Varga C. The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. Bone Marrow Transplant. 2017 09; 52(9):1349-1351. PMID: 28737773.

    Read at: PubMed
  • Published on 7/11/2017

    Browning S, Quillen K, Sloan JM, Doros G, Sarosiek S, Sanchorawala V. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood. 2017 09 14; 130(11):1383-1386. PMID: 28698204.

    Read at: PubMed
  • Published on 5/26/2017

    Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017 Aug 03; 130(5):597-605. PMID: 28550039.

    Read at: PubMed

View 106 more publications: View full profile at BUMC

View all profiles